Caspian Therapeutics
Overview
Caspian is pursuing a potentially disease-modifying approach aimed at restoring the body’s own insulin producing capacity through the selective expansion and improved function of the pancreatic β cells.
Funding and backers
Total raised
$50M
1 round on record
Latest round
$50M
Venture round · Sep 2026 · 2 mo ago
Team
51-200
employees, estimated range
The money's age
Fresh money
2 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 1
Board appointment Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors · markets.businessinsider.com
Sep 29
Launched Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes · marketscreener.com
Sep 8
Raised a round Venture round $50M · SEC Form D
2026
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2026 | $50M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Caspian Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Robert SpencerExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
Unlocking Disease-Modifying Targets for Neurodegeneration. Learn more.
Treating Chronic Disease Caused by Microbiome Dysbiosis. We develop novel, proprietary digestion-resistant carbohydrates that target…
Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance.
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell…
Lario Therapeutics are developing first-in-class disease modifying treatments for severe neurological disorders. Precision Neuroscience…
Financials
Total raised
$50M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $50M | Details |
People
Robert Spencer
Executive Officer
Troy Wilson
Director
Spike Loy
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Events and Presentations
"Our initial clinical objective is to characterize KO-7246's safety, tolerability and exposure and look for evidence of improved endogenous insulin production in people with either Type 1 or Type 2 diabetes relevant to the broader development opportunity,
Read more
Report
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (
Read more
Report
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
- Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT -SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (
Read more
Report
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
Read more
Report
Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (
Read more
Report
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
- KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models - - KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durab
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego
United States
HQ
50-200 est. staff